HEALTHCARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF OTHER INTERSTITIAL PULMONARY DISEASES IN SOUTH KOREA: A NATIONWIDE REAL-WORLD STUDY
Author(s)
Soomi Jo, BS1, Hae Sun Suh, MA, MS, PhD2.
1Department of Regulatory Science, Graduate School, Kyunghee University, Seoul, Korea, Republic of, 2College of Pharmacy, Kyung Hee University, Seoul, Korea, Republic of.
1Department of Regulatory Science, Graduate School, Kyunghee University, Seoul, Korea, Republic of, 2College of Pharmacy, Kyung Hee University, Seoul, Korea, Republic of.
OBJECTIVES: To characterize healthcare resource utilization and medical costs among patients with other interstitial pulmonary diseases in South Korea and to examine changes in these outcomes over a 13-year period following diagnosis.
METHODS: A retrospective cohort study was conducted utilizing data from the Health Insurance Review and Assessment Service, covering the entire Korean population from January 2012 to May 2024. Patients newly diagnosed with other interstitial pulmonary diseases (ICD-10: J84) were identified, with the first diagnosis date as the index date. Patients without a full year of follow-up were excluded. HCRU outcomes (inpatient admissions, duration per hospitalization, and outpatient visits) and medical costs (total, outpatient, hospitalization, and disease-related costs) were assessed annually over 13 years and reported as mean ± SD and median per patient per year.
RESULTS: A total of 283,009 patients were included (year 1: n=283,009; year 13: n=9,438); mean age was 66.3±15.7 years and 59.5% were male. From year 1 to year 13, hospitalizations decreased from 1.94±4.25 to 0.82±2.70, duration per hospitalization from 19.16±52.17 to 8.46±37.62 days, and outpatient visits from 34.77±32.75 to 20.29±24.38. Total medical costs decreased from US$4,944.93±10,487.46 (median: US$1664.32) to US$2,325.64±6,221.58 (median: US$562.54). Outpatient costs decreased from US$ 1346.22±2833.43 (median: US$781.24) to US$834.67±1658.40 (median: US$415.66), and hospitalization costs from US$3,593.67±9,811.07 (median: US$337.90) to US$1,487.84±5,786.18 (median: US$0). Disease-related costs decreased from US$1,400.89±5,738.55 (median: US$171.12) to US$68.66±898.92 (median: US$0), representing 28.3% and 3.0% of total medical costs in year 1 and year 13, respectively.
CONCLUSIONS: Patients with other ILD experienced substantial HCRU and economic burden, particularly in the first year following diagnosis. Although HCRU and medical costs were lower in later follow-up years than in the first year after diagnosis, persistent care needs underscore the importance of long-term resource planning.
METHODS: A retrospective cohort study was conducted utilizing data from the Health Insurance Review and Assessment Service, covering the entire Korean population from January 2012 to May 2024. Patients newly diagnosed with other interstitial pulmonary diseases (ICD-10: J84) were identified, with the first diagnosis date as the index date. Patients without a full year of follow-up were excluded. HCRU outcomes (inpatient admissions, duration per hospitalization, and outpatient visits) and medical costs (total, outpatient, hospitalization, and disease-related costs) were assessed annually over 13 years and reported as mean ± SD and median per patient per year.
RESULTS: A total of 283,009 patients were included (year 1: n=283,009; year 13: n=9,438); mean age was 66.3±15.7 years and 59.5% were male. From year 1 to year 13, hospitalizations decreased from 1.94±4.25 to 0.82±2.70, duration per hospitalization from 19.16±52.17 to 8.46±37.62 days, and outpatient visits from 34.77±32.75 to 20.29±24.38. Total medical costs decreased from US$4,944.93±10,487.46 (median: US$1664.32) to US$2,325.64±6,221.58 (median: US$562.54). Outpatient costs decreased from US$ 1346.22±2833.43 (median: US$781.24) to US$834.67±1658.40 (median: US$415.66), and hospitalization costs from US$3,593.67±9,811.07 (median: US$337.90) to US$1,487.84±5,786.18 (median: US$0). Disease-related costs decreased from US$1,400.89±5,738.55 (median: US$171.12) to US$68.66±898.92 (median: US$0), representing 28.3% and 3.0% of total medical costs in year 1 and year 13, respectively.
CONCLUSIONS: Patients with other ILD experienced substantial HCRU and economic burden, particularly in the first year following diagnosis. Although HCRU and medical costs were lower in later follow-up years than in the first year after diagnosis, persistent care needs underscore the importance of long-term resource planning.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD69
Topic
Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)